Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
02:30pm, Friday, 08'th May 2026
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
10:50am, Thursday, 07'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advi
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
08:30am, Thursday, 07'th May 2026
YUPELRI ® Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
10:40pm, Thursday, 30'th Apr 2026
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
05:33pm, Tuesday, 28'th Apr 2026
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such i
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
04:40pm, Tuesday, 21'st Apr 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such i
Theravance Stock Declines Around 17% in Three Months: Here's Why
02:15pm, Thursday, 16'th Apr 2026
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
10:00am, Thursday, 16'th Apr 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are a
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
10:50am, Wednesday, 15'th Apr 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
09:00am, Wednesday, 15'th Apr 2026
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, April 15, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
05:03pm, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such i
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
10:00am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
04:47am, Sunday, 05'th Apr 2026
JPMorgan Chase and Co. boosted its position in Theravance Biopharma, Inc. (NASDAQ: TBPH) by 78.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor own
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
08:48pm, Thursday, 02'nd Apr 2026
LOS ANGELES--(BUSINESS WIRE)---- $TBPH--TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm.
